High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel disease

被引：0
|
作者：
Zvuloni, M. [1 ]
Matar, M. [2 ]
Levi, R. [3 ]
Shamir, R. [1 ,2 ]
Assa, A. [2 ,4 ]
机构：
[1] Tel Aviv Univ, Sackler Fac Med, Dept Med, Tel Aviv, Israel
[2] Schneider Childrens Hosp, Inst Gastroenterol Nutr & Liver Dis, Petah Tiqwa, Israel
[3] Schneider Childrens Hosp, Pediat Dept A, Petah Tiqwa, Israel
[4] Ben Gurion Univ Negev, Dept Med, Beer Sheva, Israel
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.506
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P382
引用
收藏
页码：S395 / S395
页数：1
相关论文
共 50 条
  • [31] Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease
    Frank Hoentjen
    Ad A van Bodegraven
    World Journal of Gastroenterology, 2009, 15 (17) : 2067 - 2073
  • [32] Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease
    Hoentjen, Frank
    Van Bodegraven, Ad A.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (17) : 2067 - 2073
  • [33] Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease
    Blandizzi, C.
    Tuccori, M.
    Ferraro, S.
    Leonardi, L.
    Convertino, I.
    DRUG SAFETY, 2019, 42 (10) : 1245 - 1245
  • [34] Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
    Park, Jihye
    Cheon, Jae Hee
    GUT AND LIVER, 2021, 15 (05) : 641 - 642
  • [35] Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease
    Takahiro Amano
    Shinichiro Shinzaki
    Akiko Asakura
    Taku Tashiro
    Mizuki Tani
    Yuriko Otake
    Takeo Yoshihara
    Shuko Iwatani
    Takuya Yamada
    Yuko Sakakibara
    Naoto Osugi
    Shuji Ishii
    Satoshi Egawa
    Manabu Araki
    Yuki Arimoto
    Masanori Nakahara
    Yoko Murayama
    Ichizo Kobayashi
    Kazuo Kinoshita
    Hiroyuki Ogawa
    Satoshi Hiyama
    Narihiro Shibukawa
    Masato Komori
    Yorihide Okuda
    Takashi Kizu
    Shunsuke Yoshii
    Yoshiki Tsujii
    Yoshito Hayashi
    Takahiro Inoue
    Hideki Iijima
    Tetsuo Takehara
    Scientific Reports, 12
  • [36] Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease
    Amano, Takahiro
    Shinzaki, Shinichiro
    Asakura, Akiko
    Tashiro, Taku
    Tani, Mizuki
    Otake, Yuriko
    Yoshihara, Takeo
    Iwatani, Shuko
    Yamada, Takuya
    Sakakibara, Yuko
    Osugi, Naoto
    Ishii, Shuji
    Egawa, Satoshi
    Araki, Manabu
    Arimoto, Yuki
    Nakahara, Masanori
    Murayama, Yoko
    Kobayashi, Ichizo
    Kinoshita, Kazuo
    Ogawa, Hiroyuki
    Hiyama, Satoshi
    Shibukawa, Narihiro
    Komori, Masato
    Okuda, Yorihide
    Kizu, Takashi
    Yoshii, Shunsuke
    Tsujii, Yoshiki
    Hayashi, Yoshito
    Inoue, Takahiro
    Iijima, Hideki
    Takehara, Tetsuo
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [37] ARE ANTI-TUMOR NECROSIS FACTORS ASSOCIATED WITH WEIGHT GAIN IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE?
    Winter, Rachel W.
    Carrellas, Madeline
    Merker, Ami
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2017, 152 (05) : S410 - S410
  • [38] Inflammatory demyelinating events following treatment with anti-tumor necrosis factor
    Fromont, A.
    De Seze, J.
    Fleury, M. C.
    Maillefert, J. F.
    Moreau, T.
    CYTOKINE, 2009, 45 (02) : 55 - 57
  • [39] Liver Diseases Associated with Anti-Tumor Necrosis Factor-alpha (TNF-α) Use for Inflammatory Bowel Disease
    Coffin, Carla S.
    Fraser, Hughie F.
    Panaccione, Remo
    Ghosh, Subrata
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) : 479 - 484
  • [40] Anti-tumor necrosis factor a reverts growth hormone resistance associated with inflammatory bowel disease
    Caviglia, R
    Carotti, S
    Gentilucci, UV
    Picardi, A
    Ribolsi, M
    Afeltra, A
    Cicala, M
    GASTROENTEROLOGY, 2005, 128 (04) : A496 - A497
12345